BetterLife Pharma Inc. develops BETR-001, a proprietary non-hallucinogenic derivative of LSD and neuroplastogen, for psychiatric and neurological disorders. News about BETRF commonly covers scientific updates on BETR-001’s mechanism of action and neuroplastogenic activity, intellectual property and regulatory-preparation disclosures, and disease areas such as traumatic brain injury, post-traumatic stress disorder, cluster headache, depression and anxiety.
Company updates also include strategic partnering and conference participation, development alternatives for its viral-infection therapeutic candidate, debt settlements and warrant exercises, board and advisory appointments, and public-company disclosure matters in Canada and the U.S. OTC market.
BetterLife Pharma Inc. has partnered with Dr. John McCorvy at the Medical College of Wisconsin to conduct preclinical receptor binding studies for TD-0148A, a non-hallucinogenic LSD derivative aimed at treating cluster headaches and major depressive disorder. CEO Ahmad Doroudian highlighted the need for innovative therapies for psychiatric disorders. This partnership will explore TD-0148A's interaction with G protein coupled receptors to assist in its clinical development. BetterLife continues to focus on developing treatments for neurological conditions, with a market potential of nearly $25 billion for depression drugs by 2030.
BetterLife Pharma Inc. (CSE: BETR/ OTCQB: BETRF) announced the initiation of in vitro studies of its recombinant human interferon alpha-2b (rhIFN⍺2b or AP-003) against the Delta variant of SARS-CoV-2. Previous studies showed AP-003's potent antiviral activity against various COVID-19 strains. Results are expected within two weeks. The company's CEO emphasized the ongoing threat of COVID-19 variants and the need for effective treatments like AP-003, which could reduce hospitalization rates and severity of the disease.
BetterLife Pharma Inc. announced that its subsidiary, Altum Pharmaceuticals, alongside Pontificia Universidad Católica de Chile, received approval to conduct the IN2COVID trial in Chile. This randomized placebo-controlled trial will commence in early August, testing BetterLife's inhaled interferon alpha-2b product, AP-003, in COVID-19 patients. The trial aims to evaluate the safety and efficacy of AP-003, administered bi-daily for 10 days. BetterLife also focuses on developing compounds for neurological disorders, emphasizing the importance of effective treatment options amidst ongoing COVID-19 challenges.
BetterLife Pharma has announced funding support from Mitacs for a joint research project with Carleton University to explore the anxiolytic potential of TD-010, a compound aimed at treating anxiety and benzodiazepine dependency. TD-010, derived from honokiol, aims to provide a non-addictive alternative for patients with chronic anxiety disorders resistant to current therapies. The project will involve testing TD-010 using established models at Carleton's neuroscience department, highlighting the urgent need for safer anxiolytic treatments amidst rising benzodiazepine prescriptions.
BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF) announced its participation in the Emerging Growth Conference on July 21, 2021. CEO Dr. Ahmad Doroudian will present the company’s plans at 11:00 AM Eastern Time. Attendees will have the chance to ask questions during the session. Registered investors can also access an archived webcast post-event on EmergingGrowth.com. BetterLife focuses on developing compounds for neurological disorders, including TD-0148A for major depressive disorder and TD-010 for anxiety.
BetterLife Pharma has announced early in vitro results for its COVID-19 antiviral, rhIFN⍺2b (AP-003), showing strong antiviral activity against multiple variants, including Wuhan (EC50=0.51), Alpha, and Beta. Ongoing studies aim to validate these findings against further variants. The company has entered a clinical research agreement to trial AP-003 in COVID-19 patients. CEO Ahmad Doroudian emphasized the significance of these results in combating the pandemic and expressed commitment to broadening AP-003's efficacy against emerging variants.
BetterLife Pharma, a biotechnology company, has made significant advancements in H1 2021, particularly with its second-generation psychedelic compound, TD-0148A, aimed at treating major depressive disorders and other neurological conditions. This non-hallucinogenic LSD derivative is projected for clinical trials in H1 2022. Additionally, BetterLife is advancing its TD-010 compound for benzodiazepine dependency. The company has secured crucial partnerships for research and completed financings totaling CDN$9.16 million to support its initiatives.
BetterLife Pharma has announced funding for research into the anti-depressant effects of TD-0148A, a second-generation LSD derivative, through its collaboration with Carleton University. This funding comes from the Mitacs Accelerate program. The goal is to develop a treatment for severe depression and PTSD, addressing the unmet needs in psychiatric care. Dr. Argel Aguilar-Valles will lead the research using established models to explore TD-0148A's potential without the hallucinogenic side effects. This initiative is a significant step in BetterLife's mission to bring innovative therapies to market.
BetterLife Pharma has engaged Buchanan Communications, a leading UK-based consultancy, to enhance its corporate communications. This collaboration aims to effectively convey the Company's milestones to stakeholders, including potential investors and the media.
Additionally, Buchanan's partnership with The Conscious Fund will bolster investment in the psychedelic medicine sector, which is experiencing growth. BetterLife specializes in developing therapeutic pharmaceuticals, targeting virus infections and cancer treatment through innovative interferon-based technologies.
BetterLife Pharma Inc. will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. CEO Ahmad Doroudian will discuss the Company’s product development and pipeline, with access to the presentation available on-demand starting at 7:00 a.m. EDT. BetterLife focuses on non-hallucinogenic psychedelic therapeutics and is developing interferon-based technologies aimed at treating virus infections and certain cancers. Registration for the conference can be found here.